Ingersoll Rand Inc. · NYSE:IR
Ingersoll Rand — Merger or Acquisition (March 2024)
10 slides from Ingersoll Rand's merger presentation, Mar 25, 2024
Slide 1: Ingersoll Rand to Expand Presence in Life Sciences through Acquisition of ILC Dover
Ingersoll Rand to Expand Presence in Life Sciences through Acquisition of ILC Dover Making Life Better
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation by Ingersoll Rand Inc. (the “Company” or “Ingersoll Rand”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related the Company’s expectations regarding the performance
Slide 3: Highly attractive acquisition aligned with our strategic and financial objectives
Highly attractive acquisition aligned with our strategic and financial objectives 2023 Investor Day Attractive upfront purchase multiple of approximately 17x 2024E Adjusted EBITDA, supported by Adjusted EBITDA margins in the mid-30s and a 3-year historical organic revenue CAGR in the mid-teens, whic
Slide 4: ILC Dover extends our leadership in mission-critical technologies
ILC Dover extends our leadership in mission-critical technologies… Company Overview Product Highlights Financial Highlights 4 1 • Leader in the innovative design and production of solutions for biopharmaceutical, pharmaceutical, and Global leader in single-use ILC Dover Revenue: medical device marke
Slide 5: We have significant runway for ongoing inorganic growth
We have significant runway for ongoing inorganic growth Meaningful opportunities to expand our TAM by making disciplined acquisitions that continue to improve the quality of our portfolio Aligned Framework for Inorganic Growth 50%+ • Mission-critical flow creation is a large market with significant
Slide 6: Manufacturing expertise creates opportunities to in-source and create integrated offerings for biopharma
Manufacturing expertise creates opportunities to in-source and create integrated offerings for biopharma end market Situation Solution Future Opportunities ILC has expertise in delivering tight-tolerance ILC has used these silicone and Create a more comprehensive solution by silicone and thermoplast
Slide 7: ILC Dover is the base of a new, life science focused business in our P&ST segment
ILC Dover is the base of a new, life science focused business in our P&ST segment We are dividing our P&ST segment into two distinct businesses Business Leadership Core Products & Solutions Brands1 • Premier single-use products for powder containment and disposal Life Science • Market leading single
Slide 8: The combination with Ingersoll Rand enables a research to production model
The combination with Ingersoll Rand enables a research to production model… • Support our customers from research to commercialization, enabling natural “channel call points” allowing us to present our full portfolio across the entire Life Science workflow • Additional opportunities for M&A based on
Slide 9: Creates access for Ingersoll Rand life science solutions through established direct channel
…and creates access for Ingersoll Rand life science solutions through established direct channel ILC Customer Example: Pharmaceutical (GLP-1) Manufacturing Powder Handling Liquid Handling 1 2 3 4 5 Sampling Synthesis Sampling Filtering Dryer Pump Solutions – Peristaltic and Precision Syringe Pumps B
Slide 10: Transaction highlights
Transaction highlights • $2.325 billion upfront all-cash purchase price plus a contingent payment of up to $75 million based on 2024 results Valuation • ~17x 2024E Adjusted EBITDA based on upfront purchase price; full achievement of earnout increases multiple by <1x • Transaction not subject to any